Class

Rosen Law Firm Announces Key Deadline in Edwards Lifesciences Securities Class Action – Investors Urged to Act by December 13

by

New York — The Rosen Law Firm, recognized globally for defending investor rights, is currently notifying investors of the impending lead plaintiff deadline on December 13, 2024, in the class action lawsuit against Edwards Lifesciences Corporation. This lawsuit pertains to all individuals who acquired securities in Edwards between February 6, 2024, and July 24, 2024. These investors might be eligible for monetary recovery via a contingency fee arrangement, requiring no out-of-pocket fees. Edwards Lifesciences, listed under NYSE: EW, is primarily involved through its innovations in patient-focused medical innovations, including the critical Transcatheter Aortic Valve Replacement … Read more

Harvard-Educated Attorney Alexander Erwig Pioneers Innovative Legal Strategies in Business and Class Action Litigation

by

Los Angeles, CA — Rising through the legal echelons with a distinguished blend of academia and advocacy, Alexander Erwig, JD, has carved a niche in the world of high-stakes litigation. Specializing in business disputes, class actions, and mass tort litigation, Erwig practices law at Dovel & Luner, LLP, a firm known for tackling complex legal battles. A magna cum laude graduate from Harvard Law School, Erwig’s credentials are not just rooted in his academic excellence but also in his practical experience. Beyond the courtroom, he has contributed to the legal community as an educator at … Read more

Deadline Alert: Rosen Law Firm Reminds Edwards Lifesciences Investors of Upcoming Lead Plaintiff Deadline in Securities Class Action Lawsuit

by

NEW YORK — Rosen Law Firm, renowned for championing global investor rights, has issued a reminder about the impending lead plaintiff deadline of December 13, 2024, for those who acquired securities from Edwards Lifesciences Corporation during the period of February 6, 2024, to July 24, 2024. This deadline is crucial for investors who believe they have suffered losses due to potential misinformation by Edwards Lifesciences regarding their financial forecasts and product performance. Investors who have bought Edwards securities within this specified period may be eligible for compensation without the necessity of any out-of-pocket fees or … Read more

LILM, LILMF Investors Invited to Spearhead Securities Fraud Class Action Against Lilium N.V.

by

Investors in Lilium N.V., a prominent aerospace company specializing in electric vertical take-off and landing (eVTOL) aircraft, have been presented with the chance to lead a securities fraud lawsuit against the firm. The case emerges as allegations surface about possible misleading information provided by Lilium that might have led to investment losses. Lilium, known for its pioneering work in sustainable aviation, aimed to transform urban mobility through its innovative vehicle designs. However, recent claims suggest that the company may have been overly optimistic about the technical viability and commercial readiness of its jet prototypes. The … Read more